Vanda’s Tasimelteon: A Safe, Efficacious Drug In Search Of An Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA reviewers seem positive, but advisory committee will consider whether Non-24 is bona fide sleep disorder with identifiable patients.
You may also be interested in...
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.
Drug Safety In Pregnant Women: FDA Seeks Alternatives To Registries
Stakeholder meeting will address poor enrollment rates and other issues that undermine the utility of pregnancy registries, as well as the use of alternatives, such as case control studies and claims-based database studies.